Frequency Therapeutics CEO and leadership

David L Lucchino works at ENTREGA INC and a Co-founder, President & Chief Executive Officer at FREQUENCY THERAPEUTICS, INC.; Trustee at Babson College; and Co-Founder at Semprus BioSciences and is based in Greater Boston Area. He has worked as Board Member at Semprus BioSciences, BOARD MEMBER at AdvaMed, and Account Supervisor at Dentsu. David works or has worked as Guest Lecturer at Harvard University, MEMBER at Sloan Fellows Program, and Guest Lecturer at University of Pennsylvania. He studied at Denison University between 1987 and 1991, Syracuse University between 1996 and 1997, and MIT Sloan between 2005 and 2006.

Chris is the Chief Scientific Officer and Co-founder of Frequency Therapeutics. Chris co-founded Semprus BioSciences and served as Chief Technology Officer through the company’s acquisition by Teleflex in 2012. He led the technology team in developing medical products with surface modifications designed to reduce infection and clotting, leading to FDA/CE Mark clearance. Prior to Semprus, Chris worked as a chemical engineer at Merck Research Labs. In 2011, he was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. Chris has also been named to the Technology Review 35, the 35 innovators under 35 most likely to impact technology, and the Boston Business Journal 40 under 40. He is currently an Associate Adjunct Professor of Urology in the Yale School of Medicine. Chris holds a Ph.D. in Chemical Engineering from MIT, where he studied under Robert Langer, Sc.D., and a BSE from Princeton University.

Experienced Head of Human Resources with a demonstrated history of working in the biotechnology industry. Skilled in Talent Management, Deferred Compensation, Life Sciences, Personnel Management, and Succession Planning. Strong business development professional with a BS focused in Social Work from Colorado State University.

Dr. LeBel has served as Otonomy’s chief scientific officer since April 2009. Dr. LeBel has more than 25 years of pharmaceutical research and development experience. From 2003 to 2007, Dr. LeBel served as executive director and from 1993 to 2003 in a variety of other positions, at Amgen, Inc., a biopharmaceutical company. From 1991 to 1993, Dr. LeBel served as research scientist at Alkermes, Inc., a biopharmaceutical company. From 1990 to 1991, Dr. LeBel served as a consultant at Arthur D. Little, Inc., a management and technology consulting firm. He is also a scientific fellow of the American Academy of Otolaryngology—Head & Neck Surgery, a full member of the Association for Research in Otolaryngology and a full member of both the American Association for the Advancement of Science and the Society of Toxicology. Dr. LeBel received a doctorate in biomedical sciences/toxicology from Northeastern University and a bachelor’s degree in chemistry from the University of Detroit.

Dana C. Hilt, M.D., CMO. Dana Hilt has more than 22 years of drug development experience, primarily of CNS drugs. Most recently, he served as Senior Vice President, clinical development and Chief Medical Officer at FORUM Pharmaceuticals, where he was involved in the development of Encenicline, an alpha-7 agonist for the treatment of cognitive impairment in Schizophrenia and Alzheimer’s disease. Prior to joining FORUM, Dana held positions at various pharmaceutical companies, including Guilford Pharmaceuticals, Ascend Pharmaceuticals, and Critical Therapeutics. During this time, he was involved in the development of a variety of potential therapeutics for Parkinson’s disease, ALS, Alzheimer’s disease, oncologic diseases including malignant glioma, chronic pain, metabolic disorders, and inflammatory conditions. Prior to that, he established a Clinical Neuroscience Group at Amgen and was a faculty member at the University of Maryland School of Medicine. Dana also previously served on the staff of the NIH for five years, and has co-authored more than 100 publications and book chapters in basic and clinical neuroscience. Dana earned his M.D. from Tufts University School of Medicine in Boston and trained in Internal Medicine at Harvard Medical School and Neurology at the Johns Hopkins Hospital.

David L Lucchino works at ENTREGA INC and a Co-founder, President & Chief Executive Officer at FREQUENCY THERAPEUTICS, INC.; Trustee at Babson College; and Co-Founder at Semprus BioSciences and is based in Greater Boston Area. He has worked as Board Member at Semprus BioSciences, BOARD MEMBER at AdvaMed, and Account Supervisor at Dentsu. David works or has worked as Guest Lecturer at Harvard University, MEMBER at Sloan Fellows Program, and Guest Lecturer at University of Pennsylvania. He studied at Denison University between 1987 and 1991, Syracuse University between 1996 and 1997, and MIT Sloan between 2005 and 2006.

Chris is the Chief Scientific Officer and Co-founder of Frequency Therapeutics. Chris co-founded Semprus BioSciences and served as Chief Technology Officer through the company’s acquisition by Teleflex in 2012. He led the technology team in developing medical products with surface modifications designed to reduce infection and clotting, leading to FDA/CE Mark clearance. Prior to Semprus, Chris worked as a chemical engineer at Merck Research Labs. In 2011, he was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. Chris has also been named to the Technology Review 35, the 35 innovators under 35 most likely to impact technology, and the Boston Business Journal 40 under 40. He is currently an Associate Adjunct Professor of Urology in the Yale School of Medicine. Chris holds a Ph.D. in Chemical Engineering from MIT, where he studied under Robert Langer, Sc.D., and a BSE from Princeton University.

David L Lucchino works at ENTREGA INC and a Co-founder, President & Chief Executive Officer at FREQUENCY THERAPEUTICS, INC.; Trustee at Babson College; and Co-Founder at Semprus BioSciences and is based in Greater Boston Area. He has worked as Board Member at Semprus BioSciences, BOARD MEMBER at AdvaMed, and Account Supervisor at Dentsu. David works or has worked as Guest Lecturer at Harvard University, MEMBER at Sloan Fellows Program, and Guest Lecturer at University of Pennsylvania. He studied at Denison University between 1987 and 1991, Syracuse University between 1996 and 1997, and MIT Sloan between 2005 and 2006.

Michael Jirousek, Ph.D., is a co-founder of our company and has served as our Chief Scientific Officer since June 2008. From 2006 to 2008, Dr. Jirousek served as senior vice president of research at Sirtris Pharmaceuticals. From 2001 to 2006, Dr. Jirousek served as Senior Director and Head of the Diabetes Therapeutic Area for Pfizer Inc., a pharmaceutical company. From 1998 to 2001, Dr. Jirousek was at Abbott Laboratories, serving as a Metabolic Department Head, and prior to that he worked at Eli Lilly as a Scientist and Program Leader from 1993 to 1998 and at American Home Products Cyanamid as a Medicinal Chemist from 1991 to 1993. Dr. Jirousek was a Post-Doctoral fellow at Harvard University from 1989 to 1991 and holds a Ph.D. in chemistry from Case Western University and a B.S. in chemistry from Kent State University.